view4D pharma plc

4D Pharma's first in man study shows 'encouraging' symptom improvement

Subjects treated with Blautix showed a greater response over placebo, with the majority reporting an overall improvement in their symptoms.

Gut microbiome
"This is a true first in the field of live biotherapeutics."

4D Pharma PLC (LON:DDDD) announced that testing of its IBS live biotherapeutics treatment Blautix has shown meaningful data surrounding mechanism of action, as well as safety and tolerability, with “great efficiency”.

The first in man study was the only orally delivered live biotherapeutic to have undergone a clinical trial.  

Twice daily dosing of 24 healthy volunteers and 24 IBS subjects with either Blautix (16/24) or placebo (8/24) over a 14 day period, with a further washout period of 19-23 days. 

In common with other IBS studies, the study noted a strong placebo response.

However, following the dosing period, subjects treated with Blautix showed a greater response over placebo, with the majority reporting an overall improvement in their symptoms. 

A greater proportion of the Blautix treatment group also exhibited a reduction in hydrogen breath levels following dosing. 

Although based on a relatively small sample size, this observation is in line with pre-clinical data and strengthens the evidence of the proposed mechanism of action for Blautix in the treatment of IBS, namely altering the patient’s microbiome – altering the body’s microbial make-up.

The results show that the treatment is able to successfully deliver a single strain live biotherapeutic to the gut.

4D said the findings of this first clinical trial were encouraging and provide a solid basis for progressing Blautix into larger clinical studies and further evaluation as a potential treatment for IBS.

"This is a true first in the field of live biotherapeutics.  4D has been able to produce an orally delivered live biotherapeutic, and generate meaningful data surrounding mechanism of action, and safety and tolerability, with great efficiency,” said chief executive Duncan Peyton.

"This gives us confidence to progress to the next phase towards approval of a safe, effective treatment in IBS."

Shares were down 7% to 725p.


Quick facts: 4D pharma plc

Price: 125.8803 GBX

Market: LSE
Market Cap: £165.4 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma plc named herein, including the promotion by the Company of 4D pharma plc in any Content on the Site, the Company receives from said...


4D pharma plc merges with SPAC company Longevity Acquisition Corp

4D pharma plc (LON:DDDD) CEO Duncan Peyton tells Proactive the group is to get a cash injection of US$14.6mln through a merger with Longevity Acquisition Corporation (NASDAQ:LOAC), a special purpose acquisition company. Peyton says the merger will accelerate and de-risk 4D's admission to...

3 days, 19 hours ago

2 min read